- Home
- FURY vs CRVO Comparison
FURY vs CRVO Comparison
Compare FURY & CRVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FURY | CRVO |
|---|---|---|
| Founded | 2008 | 2001 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 97.7M | 89.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | FURY | CRVO |
|---|---|---|
| Price | $0.59 | $8.22 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $1.40 | ★ $21.50 |
| AVG Volume (30 Days) | ★ 554.5K | 88.3K |
| Earning Date | 11-13-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $6,159,786.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.35 | $1.80 |
| 52 Week High | $0.89 | $16.94 |
Technical Indicators
Market Signals| Indicator | FURY | CRVO |
|---|---|---|
| Relative Strength Index (RSI) | 53.63 | 48.57 |
| Support Level | $0.50 | $8.50 |
| Resistance Level | $0.63 | $10.00 |
| Average True Range (ATR) | 0.05 | 0.72 |
| MACD | 0.01 | 0.10 |
| Stochastic Oscillator | 71.38 | 43.61 |
Price Performance
Historical ComparisonAbout FURY Fury Gold Mines Limited
Fury Gold Mines Ltd is a Canadian-focused exploration and development company strategically positioned in three prolific mining regions: James Bay, Quebec; the Golden Triangle, British Columbia; and the Kitikmeot Region Nunavut. Its projects include Eau Claire, Homestake Ridge, Committee Bay, Eleonore South JV, and Gibson MacQuoid.
About CRVO CervoMed Inc.
CervoMed Inc is a clinical stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.